Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population
Open Access
- 1 February 2002
- Vol. 87 (2) , 131-135
- https://doi.org/10.1136/heart.87.2.131
Abstract
Background: Conflict exists regarding the usefulness of measuring plasma B type natriuretic peptide (BNP) concentrations for identifying impaired left ventricular (LV) systolic function during mass screening. Various cardiac abnormalities, regardless of degree of LV dysfunction, are prone to carry a high risk of cardiovascular events. Objective: To examine the validity of plasma BNP measurement for detection of various cardiac abnormalities in a population with a low prevalence of coronary heart disease and LV systolic dysfunction. Design and setting: Participants in this cross sectional study attended a health screening programme in Iwate, northern Japan. Plasma BNP concentrations were determined in 1098 consecutive subjects (mean age 56 years) by direct radioimmunoassay. All subjects underwent multiphasic health checkups including physical examination, ECG, chest radiography, and transthoracic echocardiography. Results: Conventional diagnostic methods showed 39 subjects to have a wide range of cardiac abnormalities: lone atrial fibrillation or flutter in 11; previous myocardial infarction in seven; valvar heart disease in seven; hypertensive heart disease in six; cardiomyopathy in six; atrial septal defect in one; and cor pulmonale in one. No subjects had a low LV ejection fraction (< 40%). To assess the utility of plasma BNP measurement for identification of such patients, receiver operating characteristic analysis was performed. The optimal threshold for identification was a BNP concentration of 50 pg/ml with sensitivity of 89.7% and specificity of 95.7%. The area under the receiver operating characteristic curve was 0.970. The positive and negative predictive values at the cutoff level were 44.3% and 99.6%, respectively. Conclusion: Measurement of plasma BNP concentration is a very efficient and cost effective mass screening technique for identifying patients with various cardiac abnormalities regardless of aetiology and degree of LV systolic dysfunction that can potentially develop into obvious heart failure and carry a high risk of a cardiovascular event.Keywords
This publication has 34 references indexed in Scilit:
- Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the communityHeart, 2000
- Biochemical detection of left-ventricular systolic dysfunctionThe Lancet, 1998
- Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban populationThe Lancet, 1997
- Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment.Heart, 1996
- Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunctionThe American Journal of Cardiology, 1996
- Ambulatory Blood Pressure Monitoring in Evaluating the Prevalence of Hypertension in Adults in Ohasama, a Rural Japanese Community.Hypertension Research, 1996
- Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease.Heart, 1993
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation, 1978
- Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asynergyThe American Journal of Cardiology, 1976
- Clinical features of unrecognized myocardial infarction—Silent and symptomaticThe American Journal of Cardiology, 1973